These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 12678768)

  • 21. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.
    Wilstermann AM; Osheroff N
    Curr Top Med Chem; 2003; 3(3):321-38. PubMed ID: 12570766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor cell death induced by topoisomerase-targeting drugs.
    Li TK; Liu LF
    Annu Rev Pharmacol Toxicol; 2001; 41():53-77. PubMed ID: 11264450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
    Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
    Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topoisomerase I poisons and suppressors as anticancer drugs.
    Bailly C
    Curr Med Chem; 2000 Jan; 7(1):39-58. PubMed ID: 10637356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
    Marx G; Zhou H; Graves DE; Osheroff N
    Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA topoisomerase i as a transcription protein and a lethal cellular toxin.
    Lotito L; Ferri F; Russo A; Capranico G
    Ital J Biochem; 2007 Jun; 56(2):122-9. PubMed ID: 17722653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
    Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R
    Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutagenic properties of topoisomerase-targeted drugs.
    Baguley BC; Ferguson LR
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):213-22. PubMed ID: 9748584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugging topoisomerases: lessons and challenges.
    Pommier Y
    ACS Chem Biol; 2013 Jan; 8(1):82-95. PubMed ID: 23259582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.
    Nitiss JL
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1512-6. PubMed ID: 12431029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA sequence selectivity of topoisomerases and topoisomerase poisons.
    Capranico G; Binaschi M
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):185-94. PubMed ID: 9748568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of new anti-cancer agents based on topoisomerase poisons targeted to specific DNA sequences.
    Arimondo PB; Hélène C
    Curr Med Chem Anticancer Agents; 2001 Nov; 1(3):219-35. PubMed ID: 12678755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA topoisomerase targeting drugs: mechanisms of action and perspectives.
    Malonne H; Atassi G
    Anticancer Drugs; 1997 Oct; 8(9):811-22. PubMed ID: 9402307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A model for tumor cell killing by topoisomerase poisons.
    Zhang H; D'Arpa P; Liu LF
    Cancer Cells; 1990 Jan; 2(1):23-7. PubMed ID: 2167111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents.
    Pogorelčnik B; Perdih A; Solmajer T
    Curr Med Chem; 2013; 20(5):694-709. PubMed ID: 23210851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA Topoisomerases as Targets for Antibacterial Agents.
    Hiasa H
    Methods Mol Biol; 2018; 1703():47-62. PubMed ID: 29177732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topoisomerase I inhibitors: camptothecins and beyond.
    Pommier Y
    Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents.
    Okoro CO; Fatoki TH
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.